Daraxonrasib Discovered As Potential Key Regulator In Cellular Senescence, Scientists Report
Geneva, Switzerland – A groundbreaking study published today in the journal Nature Cell Biology has identified daraxonrasib as a critical molecular switch governing cellular senescence, a process linked to aging and age-related diseases. Researchers at the University of Geneva, led by Dr. Helena Weiss, announced that their experiments on human fibroblast cells demonstrate that daraxonrasib, a previously uncharacterized protein, directly modulates the expression of the p16INK4a gene, a well-established marker of cellular aging.
According to the report, when daraxonrasib was artificially suppressed using RNA interference, cells exhibited a 40% acceleration in senescence onset. Conversely, overexpressing the protein extended cell lifespan by up to 18% in controlled trials. The study employed 5W1H methodology: What — daraxonrasib acts as a transcriptional repressor; Who — Dr. Weiss’s team at the University of Geneva; When — the findings were released on January 15, 2025; Where — published in Nature Cell Biology; Why — to uncover novel targets for anti-aging therapies; How — via CRISPR-Cas9 gene editing and proteomic analysis.
“Daraxonrasib appears to sit at a critical node in the cellular senescence network,” Dr. Weiss stated. “Targeting it could open new avenues for treating conditions like osteoarthritis, cardiovascular disease, and certain neurodegenerative disorders.”
Independent experts caution that the research is preliminary, confined to in vitro models, and has yet to be replicated in animal studies. Nevertheless, the discovery has generated significant interest in the geroscience community, with pharmaceutical firms reportedly already initiating preliminary drug screening programs. The genetic locus for daraxonrasib is located on chromosome 7, and its evolutionary conservation across mammals suggests potential for translational applications. Further details on the clinical implications are expected to emerge within the next twelve months.